EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome

Jeffrey A Mensah iD, Kristina Johnson, Tia Freeman, Christopher A Reilly iD, Joseph E Rower iD, Cameron S Metcalf iD, Karen S Wilcox iD

Epilepsia · 2024

DOI: 10.1111/epi.18104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2024. Verfasst von Jeffrey A Mensah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Disease Models, Animal, Clobazam, Anticonvulsants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDA NIH HHS, Donald R. Gehlert Fellowship, University of Utah College of Pharmacy, National Institute of Neurological Disorders and Stroke, Epilepsy Therapy Screening Program, National Institutes of Health, and Department of Health and Human….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The current standard of care for Dravet syndrome (DS) includes polytherapy after inadequate seizure control with one or more monotherapy approaches. Treatment guidelines are often based on expert opinions, and finding an optimal balance between seizure control and adverse drug effects can be challenging. This study utilizes the efficacy and pharmacokinetic assessment of a second‐line treatment regimen that combines clobazam and sodium valproate with an add‐on drug as a proof‐of‐principle approach to establish an effective therapeutic regimen in a DS mouse model.

Methods

We evaluated the efficacy of add‐on therapies stiripentol, cannabidiol, lorcaserin, or fenfluramine added to clobazam and sodium valproate against hyperthermia‐induced seizures in Scn1a A1783V/WT mice. Clobazam, N‐desmethyl clobazam (an active metabolite of clobazam), sodium valproate, stiripentol, and cannabidiol concentrations were quantified in plasma and brain using liquid chromatography–tandem mass spectrometry for the combinations deemed effective against hyperthermia‐induced seizures. The concentration data were used to calculate pharmacokinetic parameters via noncompartmental analysis in Phoenix WinNonLin.

Results

Higher doses of stiripentol or cannabidiol, in combination with clobazam and sodium valproate, were effective against hyperthermia‐induced seizures in Scn1a A1783V/WT mice. In Scn1a WT/WT mice, brain clobazam and N‐desmethyl clobazam concentrations were higher in the triple‐drug combinations than in the clobazam monotherapy. Stiripentol and cannabidiol brain concentrations were greater in the triple‐drug therapy than when given alone. Significance A polypharmacy strategy may be a practical preclinical approach to identifying efficacious compounds for DS. The drug–drug interactions between compounds used in this study may explain the potentiated efficacy of some polytherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicDisease Models, AnimalClobazamAnticonvulsantsValproic AcidDioxolanesCannabidiolHyperthermiaAnimalsMiceDrug Therapy, CombinationNAV1.1 Voltage-Gated Sodium ChannelSeizuresDose-Response Relationship, DrugMice, TransgenicMaleFenfluramine

Stichwörter der Autor:innen

Dravet syndromeantiseizure drugshyperthermia‐induced seizure modelpharmacokineticstriple‐drug therapy

Substanzen

ClobazamAnticonvulsantsValproic AcidstiripentolDioxolanesCannabidiolNAV1.1 Voltage-Gated Sodium ChannelScn1a protein, mouseFenfluramine

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
  • Contract Site of the National Institute of Neurological Disorders and Stroke Epilepsy Therapy Screening Program, Salt Lake City, Utah, USA.
  • Center for Human Toxicology, Salt Lake City, Utah, USA.

ORCID-Profile: Jeffrey A Mensah, Christopher A Reilly, Joseph E Rower, Cameron S Metcalf, Karen S Wilcox

Förderung

  • NIDA NIH HHS
  • Donald R. Gehlert Fellowship, University of Utah College of Pharmacy
  • National Institute of Neurological Disorders and Stroke, Epilepsy Therapy Screening Program, National Institutes of Health, and Department of Health and Human…
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Mensah, J. A., Johnson, K., Freeman, T., Reilly, C. A., Rower, J. E., Metcalf, C. S., & Wilcox, K. S. (2024). Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome. Epilepsia. https://doi.org/10.1111/epi.18104

Vancouver

Mensah JA, Johnson K, Freeman T, Reilly CA, Rower JE, Metcalf CS, et al. Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome. Epilepsia. 2024. doi:10.1111/epi.18104

BibTeX
@article{Mensah2024,
  author = {Mensah, Jeffrey A and Johnson, Kristina and Freeman, Tia and Reilly, Christopher A and Rower, Joseph E and Metcalf, Cameron S and Wilcox, Karen S},
  title = {Utilizing an acute hyperthermia‐induced seizure test and pharmacokinetic studies to establish optimal dosing regimens in a mouse model of Dravet syndrome},
  journal = {Epilepsia},
  year = {2024},
  doi = {10.1111/epi.18104}
}
Kostenlos starten →